SAB--a promising new treatment to improve remission rates in AML in the elderly?
This short report presents the results of a comparison of complete remission rates and reasons for failure, between two series of patients aged 60 years or over with acute myeloid leukaemia (AML), and discusses their interpretation.
Wheatley
Keith
K
University of Birmingham Clinical Trials Unit, Park Grange, 1 Somerset Road, Edgbaston, Birmingham B15 2RR, UK. k.wheatley@bham.ac.uk
D000208:Acute Disease; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D018572:Disease-Free Survival; D006801:Humans; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D012074:Remission Induction; D013866:Thioguanine / Q000008:administration & dosage
D003561:Cytarabine; D013866:Thioguanine; D003630:Daunorubicin